Similar articles

• Graft versus host disease prophylaxis today.

  Martelli MF, Aversa F. Martelli MF, et al. Bone Marrow Transplant. 1991;7 Suppl 2:112-6. Bone Marrow Transplant. 1991. PMID: 1908726 Review. No abstract available.
• XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.

  Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE. Koehler M, et al. Bone Marrow Transplant. 1994 May;13(5):571-5. Bone Marrow Transplant. 1994. PMID: 7519937
• Monoclonal anti TNF alpha antibody in the treatment of acute GvHD refractory both to corticosteroids and anti IL-2 R antibody.

  Hervé P, Racadot E, Wijdenes J, Flesch M, Tiberghien P, Bordigoni P, Holler E, Powles M, Bourdeau M, Wilmer E, et al. Hervé P, et al. Bone Marrow Transplant. 1991;7 Suppl 2:149. Bone Marrow Transplant. 1991. PMID: 1878688 Clinical Trial. No abstract available.
• Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.

  Antin JH, Bierer BE, Smith BR, Guinan EC, Provost MM, Ferrara J, Macklis RM, Tarbell NJ, Blythman H, Bouloux C, et al. Antin JH, et al. Prog Clin Biol Res. 1990;333:207-15. Prog Clin Biol Res. 1990. PMID: 1689852 No abstract available.
• Graft-versus-leukemia without graft-versus-host disease: an elusive goal of bone marrow transplantation.

  Champlin R. Champlin R. Semin Hematol. 1992 Jul;29(3 Suppl 2):46-52. Semin Hematol. 1992. PMID: 1509294 Review. No abstract available.